Ridgeland Medical Clinic | |
587 Highway 51 Ste T Ridgeland MS 39157-2567 | |
(601) 790-7711 | |
(601) 790-7712 |
Full Name | Ridgeland Medical Clinic |
---|---|
Speciality | Family Medicine |
Location | 587 Highway 51 Ste T, Ridgeland, Mississippi |
Authorized Official Name and Position | Jody Adams (NURSE PRACTITIONER) |
Authorized Official Contact | 6017907711 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Ridgeland Medical Clinic 587 Highway 51 Ste T Ridgeland MS 39157-2567 Ph: (601) 790-7711 | Ridgeland Medical Clinic 587 Highway 51 Ste T Ridgeland MS 39157-2567 Ph: (601) 790-7711 |
NPI Number | 1053917849 |
---|---|
Provider Enumeration Date | 12/08/2020 |
Last Update Date | 12/08/2020 |
Medicare PECOS PAC ID | 9032524400 |
---|---|
Medicare Enrollment ID | O20210217000175 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1053917849 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | (* (Not Available)) | Primary |
Provider Name | Barbara A Bradley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124064068 PECOS PAC ID: 1951203181 Enrollment ID: I20040127000212 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Massie Headley |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1649249426 PECOS PAC ID: 0446145288 Enrollment ID: I20040219000497 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Jody T Adams |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780652362 PECOS PAC ID: 1456246131 Enrollment ID: I20040220000479 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Laurie B Robinson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053355024 PECOS PAC ID: 7911976352 Enrollment ID: I20041001000163 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | William D. Whitton |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1790754307 PECOS PAC ID: 8325027063 Enrollment ID: I20041110000268 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Calvin Ramsey |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508919648 PECOS PAC ID: 0143131037 Enrollment ID: I20111108000829 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Amanda B Greene |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083040562 PECOS PAC ID: 0547277980 Enrollment ID: I20140617002012 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Leah S Mcgehee |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1265825962 PECOS PAC ID: 5193044931 Enrollment ID: I20150429001873 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Sabrina B Matthews |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043662430 PECOS PAC ID: 7416953047 Enrollment ID: I20160913000669 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Lonnie L Moore |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962852988 PECOS PAC ID: 8820386451 Enrollment ID: I20161013001187 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Jason Brian Copeland |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326538315 PECOS PAC ID: 6901157874 Enrollment ID: I20180918000176 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Provider Name | Mary Hannah Bucklew |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467024901 PECOS PAC ID: 0446657340 Enrollment ID: I20210920002337 |
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
News Archive
To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.
Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.
The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.
› Verified 7 days ago
Pmb Family Medical, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 710 Highland Colony Pkwy Ste A-1, Ridgeland, MS 39157 Phone: 601-398-9886 | |
Fitvisits Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 731 S Pear Orchard Rd Ste 16, Ridgeland, MS 39157 Phone: 662-213-6555 | |
Natural Health Project Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 555 Highway 51, Ridgeland, MS 39157 Phone: 601-856-2383 Fax: 601-856-3955 | |
Advance Medical House Calls & Family Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 299 Highway 51 Ste F1, Ridgeland, MS 39157 Phone: 601-397-4079 Fax: 601-398-2149 | |
Integrated Medical And Wellness Clinic Of Mississippi Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 212 Draperton Ct, Ridgeland, MS 39157 Phone: 769-300-9040 Fax: 769-300-9055 | |
Magnolia Premier Medical Group Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1000 Highland Colony Pkwy Ste 35203, Ridgeland, MS 39157 Phone: 601-613-5682 Fax: 601-372-3059 |